Thyroid Disease CARE Act of 2025
Summary
HR6897 (Thyroid Disease CARE Act) authorizes $30M/year for five years for thyroid disease research and improved diagnostics. The bill is in early stage — referred to House Energy and Commerce Committee on December 18, 2025. Real market data shows diagnostic stocks trending negative over the past 30 days, with Labcorp down 1.53% and Abbott down 11.85%. Any impact is procedural and speculative at this stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR6897 authorizes $30M/year for five years for thyroid research — but no funds are allocated, and the bill is stuck in committee with no action since introduction
- 2.The bill has only one cosponsor and a Democratic lead in a Republican House — passage probability is low in the 119th Congress
- 3.Even if fully funded, the $150M total is immaterial to major diagnostics companies (Q1 2026 revenue for $DGX alone exceeds $2.3 billion)
- 4.Market data shows diagnostic stocks trending negative; any bill-driven catalyst is speculative at this stage
Market Implications
HR6897 is a procedural bill with no near-term market impact. Real market data shows diagnostic stocks $DGX, $LH, and all declining over the past 30 days (down 0.41%, 1.53%, and 11.85% respectively), driven by broader healthcare sector pressures, not legislative events. Thermo Fisher ($TMO) is also down 3.42% in the same period. The $30M annual authorization is too small to move pricing on these stocks even if appropriated. Investors should not trade diagnostic tickers based on this bill. The only potential catalyst would be the bill advancing to a committee markup or receiving a Senate companion — neither of which has occurred.
Full Analysis
-
What happened: Representative Stevens (D-MI) introduced HR6897, the Thyroid Disease CARE Act of 2025, on December 18, 2025. The bill was referred to the House Committee on Energy and Commerce, where it remains with no further action. With only one cosponsor (Rep. Underwood, D-IL), the bill has narrow bipartisan support, and the current House majority (Republicans) has not advanced it.
-
The money trail: Section 2(c) authorizes $30 million per fiscal year for 2026 through 2030 — a total of $150 million. This is an AUTHORIZATION, not an appropriation. The actual spending requires a separate appropriations bill passed by both chambers. Given the current fiscal environment and the bill's early stage, no funds are currently allocated.
-
Structural winners and losers: Companies in thyroid diagnostics and research tools ($DGX, $LH, $TMO, , ) would be the most directly exposed if the bill progresses and appropriations are made. However, $150 million over five years is modest — roughly equivalent to 0.1-0.3% of annual revenue for these companies. No company receives a direct earmark.
-
Market data context: As of April 30, 2026, thyroid diagnostic companies show weakness. trades at $90.50, near its 52-week low of $90.29, with a 30-day decline of 11.85%. $LH is down 1.53% over 30 days to $262.73. $DGX is essentially flat over 30 days (-0.41%) at $195.17. Research tool provider $TMO has fallen 3.42% in 30 days to $474.70. These moves are unrelated to a bill that has been dormant for over four months.
-
Timeline: The bill requires committee markup in Energy and Commerce, House floor passage, Senate companion introduction and passage, then presidential signature. With a single cosponsor and a Democratic lead sponsor in a Republican-controlled House, the probability of passage in the 119th Congress is low. No hearings or markups have been scheduled as of April 30, 2026.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Authorization of $30M/year for research to improve diagnostic techniques for thyroid disease
Who must act
HHS Secretary, in consultation with the National Academies — must conduct or support research and report to Congress
What happens
Federal grants and contracts will be issued for thyroid disease diagnostic research and improved diagnostic techniques
Stock impact
Quest Diagnostics is a leading provider of clinical lab testing services including thyroid panels (TSH, T4, T3), and could capture a share of new federally funded research contracts for improved thyroid diagnostics
What the bill does
Authorization of $30M/year for research to improve diagnostic techniques for thyroid disease
Who must act
HHS Secretary, in consultation with the National Academies — must conduct or support research and report to Congress
What happens
Federal grants and contracts will be issued for thyroid disease diagnostic research and improved diagnostic techniques
Stock impact
Labcorp is a direct peer to Quest in thyroid diagnostics and clinical testing — similar potential to compete for research grants for improved thyroid diagnostic techniques
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
SUPPORT for Patients and Communities Reauthorization Act of 2025
CHOICE for Veterans Act of 2025
ASAP Act
Increasing Access to Lung Cancer Screening Act
Supporting Healthy Moms and Babies Act
Reducing Hereditary Cancer Act
Access to Breast Cancer Diagnosis Act of 2025
Lung Cancer Screening and Prevention Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Securing America’s Defense Supply Chains and Ensuring Domestic Acquisition of Critical Materials
This executive order restricts waivers for foreign-sourced critical materials in defense contracts, effective January 1, 2027, and mandates that defense contractors map their supply chains from raw materials to end products, vet subcontractors for risks, and prohibit covered materials from unreliable foreign suppliers. It directs the Secretary of War to enforce strict compliance, including requiring mitigation plans for any non-compliant materials and establishing penalties for fraud or willful noncompliance.
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →